Applied Biologics announced on November 11, 2026, that it had entered a research collaboration agreement with Dartmouth College’s Thayer School of Engineering to work on computational protein engineering and therapeutic protein design, initially including its preclinical osteoarthritis gene therapy program APPB-515.
The collaboration, established through Dartmouth’s Industry PhD program, will integrate computational approaches to protein structure, dynamics and molecular engineering with Applied Biologics’ therapeutic development activities. Its scope covers computational design, engineering and evaluation of therapeutic protein variants for potential use in gene-based therapies. The stated objectives are to improve understanding of protein structure-function relationships, predict the effects of amino-acid modifications and guide the design and optimization of engineered therapeutic proteins.
APPB-515 and Experimental Validation
APPB-515 integrates gene-delivery technologies and protein engineering to pursue therapies directed at biological processes associated with progressive joint degeneration. Applied Biologics describes the program as disease-modifying; it remains preclinical.
The research is expected to complement Applied Biologics’ existing capabilities in recombinant protein production, analytical characterization, functional testing and biological evaluation. The company aims to combine computational modeling with experimental validation to identify and optimize engineered candidates more systematically for potential advancement into preclinical development. That approach connects computational variant design with laboratory assessment, making experimental validation part of the engineering process.
Industry PhD Research Framework
Dartmouth’s Industry PhD option is designed for professionals who conduct doctoral research at their current workplaces with a Dartmouth Engineering faculty advisor while continuing their careers. Eligible applicants must already work for the organization where they propose to conduct that research. The program does not arrange employment or match students with industry partners.
The option generally begins with a memorandum of understanding between Dartmouth and the sponsoring company covering intellectual-property management. Depending on the project, ownership may rest with the company, Dartmouth or both. When Dartmouth solely or jointly owns the intellectual property, the company has an option to negotiate license terms.
Dartmouth’s wider protein-engineering research includes active projects in novel protein-expression systems, therapeutic protein deimmunization and vaccine design. Listed research subfields also include cell-based protein purification systems, cellular engineering of protein-expression hosts, glyco-engineering and protein-engineering tools for immunology.
Pipeline and Development Status
Beyond APPB-515, Applied Biologics lists APPB-429, a preclinical gene therapy program targeting diabetic peripheral neuropathy, and BIOxHEAL, an investigational biologic in Phase 3 clinical development for chronic wounds. The collaboration also creates opportunities for original scientific research, academic publication and continued development of computational approaches to therapeutic protein engineering.
The announcement qualifies the research and potential therapeutic applications as investigational and states that successful development or commercialization cannot be assured. The agreement’s practical significance lies in its planned connection between computational design and experimental validation. The key test for the collaboration is whether that integration yields engineered candidates suitable for further preclinical work.
